News & Updates
Filter by Specialty:
Use of RAS inhibitors associated with lower cancer risk in T2D
A real-world study of over 250,000 type 2 diabetes (T2D) patients from Hong Kong has found that use of renin-angiotensin-system inhibitors (RASIs) is independently associated with reduced risk of cancer, including diabetes-related cancers and cancer-specific mortality in diabetes.
Use of RAS inhibitors associated with lower cancer risk in T2D
03 Oct 2022
Alcohol consumption ups risk of CVD, all-cause mortality in men
Recent evidence suggests that drinking alcoholic beverages is associated with cardiovascular diseases (CVD), including coronary artery disease (CAD), and all-cause mortality.
Alcohol consumption ups risk of CVD, all-cause mortality in men
01 Oct 2022
Absence of standard modifiable cardiovascular risk factors tied to poor outcomes in type 2 AMI
Among patients with type 2 acute myocardial infarction (AMI), the absence of standard modifiable cardiovascular risk factors (SMuRF) appears to worsen poor outcomes, such as mortality, stroke, and major adverse cardiovascular and cerebrovascular events (MACCE), a new study has found.
Absence of standard modifiable cardiovascular risk factors tied to poor outcomes in type 2 AMI
01 Oct 2022
AF increases susceptibility to stroke associated with air pollution exposure
Atrial fibrillation (AF) exacerbates the effect of air pollution exposure on acute ischaemic stroke outcomes, such that AF patients are more likely to develop stroke when exposed to increasing levels of smog (O3) and carbon monoxide (CO) compared with those who have no AF, according to a Singapore study.
AF increases susceptibility to stroke associated with air pollution exposure
30 Sep 2022
Apixaban better than enoxaparin for extended-duration VTE prophylaxis after surgery
Apixaban is not inferior to enoxaparin for extended-duration venous thromboembolic event (VTE) prophylaxis (EP) following urologic oncology surgery, reveals a study. In addition, apixaban is associated with fewer major complications and compliance-related adverse events.
Apixaban better than enoxaparin for extended-duration VTE prophylaxis after surgery
29 Sep 2022
Renal denervation bounces back in 3-year follow-up study
Following negative primary results, the final follow-up of the SYMPLICITY HTN-3 trial takes a turn for the better, demonstrating significant blood pressure (BP) reductions with renal denervation (RDN) in patients with uncontrolled hypertension (HTN).
Renal denervation bounces back in 3-year follow-up study
29 Sep 2022
Urological prosthetic surgery: Which men are at risk of postoperative thromboembolism?
Some men who undergo artificial urinary sphincter (AUS) and inflatable penile prosthesis (IPP) surgery encounter a venous thromboembolism (VTE) event within 90 days of their operation, reports a study.